Welcome to our dedicated page for Merck & news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & stock.
Merck & Co., Inc. reports news across a global pharmaceutical business known as MSD outside the United States and Canada. Company updates center on human health products for areas such as oncology, cardiometabolic disease and infections; vaccines including Gardasil; and Merck Animal Health medicines, devices and customer-support systems.
Recurring developments include FDA approvals, clinical and regulatory disclosures, research publications, pipeline additions, business development transactions, material agreements, capital-structure updates, governance matters, and operating and financial results. Recent themes include the approved HIV-1 regimen IDVYNSO, investigational programs such as enlicitide decanoate and TERN-701, technology partnerships for research, manufacturing and commercial functions, and animal health digital engagement initiatives.
Merck (NYSE: MRK) reported that the FDA granted Breakthrough Therapy designation to calderasib (MK-1084), an investigational oral KRAS G12C inhibitor, combined with KEYTRUDA for first-line treatment of advanced or metastatic KRAS G12C‑mutant NSCLC with PD‑L1 TPS ≥1%.
The designation is supported by positive Phase 1 KANDLELIT‑001 data and is accompanied by an extensive KANDLELIT Phase 3 program across NSCLC and CRC. Calderasib is being developed in collaboration with Taiho and Astex.
Merck (NYSE: MRK) announced that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, will join a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, at 10:30 a.m. ET.
A live audio webcast of the presentation will be available to investors, analysts, media, and the public via an online weblink.
Merck (NYSE: MRK) declared a third-quarter 2026 quarterly dividend of $0.85 per share on its common stock. The dividend will be paid on July 8, 2026 to shareholders of record as of the close of business on June 15, 2026.
Merck (NYSE:MRK) received a positive opinion from the EU CHMP for KEYTRUDA plus Padcev as perioperative treatment for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin chemotherapy, including the subcutaneous KEYTRUDA SC formulation.
The Phase 3 KEYNOTE-905 trial showed the combination cut event-free survival risk by 60% (HR=0.40) and death risk by 50% (HR=0.50) versus surgery alone, with higher pathologic complete response (57.1% vs 8.6%). An EC decision on EU marketing authorization is expected by Q3 2026.
Synergis Software (NYSE:ED) launched Adept Cloud, a cloud-native SaaS engineering document management platform for asset-intensive industries such as manufacturing, utilities, oil and gas, chemicals, pharmaceuticals, and mining. It delivers the full Adept capabilities in a browser-based, fully hosted and continuously updated environment.
Adept Cloud includes built-in Adept AI to surface engineering information faster and support document-intensive work. Plans—Essentials, Professional, and Enterprise—offer unlimited users with no per-seat costs. Synergis highlights strong user feedback, with 95% of verified G2 reviews rated four or five stars.
Merck (NYSE:MRK) reported that the pivotal Phase 3 TroFuse-005 trial of investigational TROP2-directed ADC sacituzumab tirumotecan (sac-TMT) in certain patients with advanced or recurrent endometrial cancer met its primary endpoints of overall survival (OS) and progression-free survival (PFS) versus physician’s choice chemotherapy.
The study also met its key secondary endpoint of objective response rate and showed a safety profile consistent with prior sac-TMT studies, with no new safety signals. According to Merck, TroFuse-005 is the first global Phase 3 trial to show statistically significant OS and PFS benefit for a TROP2 ADC in this setting.
Merck (NYSE:MRK) will present data from more than 100 oncology abstracts across over 25 cancer types at ASCO 2026 (May 29–June 2). Key highlights include 5-year follow-up from KEYNOTE-942 for intismeran autogene plus KEYTRUDA in melanoma and final analysis of KEYNOTE-522 in early-stage TNBC.
Additional Phase 3 data feature sacituzumab tirumotecan in NSCLC, KEYTRUDA plus Trodelvy in metastatic TNBC, and long-term results across genitourinary, gastrointestinal, gynecologic and biomarker-focused studies. Merck will also host an Oncology Investor Event on June 1, 2026.
Merck (NYSE: MRK) published a Science paper (May 7, 2026) describing a large-scale biocatalytic synthesis of enlicitide decanoate, an investigational oral PCSK9 inhibitor.
The paper details enzyme-enabled peptide fragment formation, coupling, macrocyclization, and crystallization-based purifications that enable scalable, sustainable manufacture of this macrocyclic peptide.
Merck Animal Health selected Salesforce (NYSE: CRM) Agentforce Life Sciences to create a unified, 360-degree customer engagement platform across veterinarians, pet owners, and production animal farmers. The deployment uses Agentforce 360 and Data 360 to consolidate device data, prescription history, omni-channel service, personalized marketing, subscriptions, warranties, and sales workflows.
The initiative aims to reduce waste and cost to serve, improve access to medicines and devices, increase acquisition and retention, and centralize monitoring and biopharma systems onto a single platform.
Merck (NYSE: MRK) completed the acquisition of Terns Pharmaceuticals on May 5, 2026, paying $53.00 per share in cash and making Terns a wholly‑owned subsidiary.
The deal covers ~86.36% of Terns shares tendered and converts remaining shares into the same cash consideration; TERN‑701, an oral allosteric BCR::ABL1 inhibitor with FDA Breakthrough Therapy Designation for certain CML patients, joins Merck’s oncology pipeline. The transaction is expected to be treated as an asset acquisition with a $5.8 billion R&D charge and a ~$0.12 EPS negative impact in 2026.